Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Clinical Trial ID NCT04719221

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04719221

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).	Eur Heart J	2014	9.73
2	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.	Eur Heart J	2013	9.54
3	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.	J Am Coll Cardiol	2011	6.35
4	2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: A report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in collaboration with the Society of Thoracic Surgeons and Society for Vascular Medicine.	J Am Coll Cardiol	2012	1.36
5	The NCDR CathPCI Registry: a US national perspective on care and outcomes for percutaneous coronary intervention.	Heart	2013	1.28
6	In vivo characterization of coronary plaques: novel findings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy.	Eur Heart J	2011	1.24
7	Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction.	JACC Cardiovasc Interv	2013	1.21
8	Plaque Characterization to Inform the Prediction and Prevention of Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention: The CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow).	JACC Cardiovasc Interv	2015	1.08
9	Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy).	J Am Coll Cardiol	2013	0.93
10	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and In Vivo Study.	Arterioscler Thromb Vasc Biol	2015	0.84
11	Multimodality direct coronary imaging with combined near-infrared spectroscopy and intravascular ultrasound: initial US experience.	Catheter Cardiovasc Interv	2012	0.82
12	ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance.	Circulation	2013	0.81
13	Intracoronary Imaging, Cholesterol Efflux, and Transcriptomes after Intensive Statin Treatment: The YELLOW II study.	J Am Coll Cardiol	2016	0.76